Loading
companiesCompany
Shanghai Kechow Pharma
Shanghai Kechow Pharma is a China-based pharmaceutical company running 3 late-stage cancer trials of tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood.
Also called: Shanghai Kechow Pharma, Inc.
Overview
Shanghai Kechow Pharma, based in Shanghai, China, is a pharmaceutical company. Kechow Pharma is a Shanghai-based pharmaceutical company engaged in independent, intellectual-property-driven innovative drug research and development, focused on oncology and free-radical-related diseases. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood. The largest, NCT06008106 (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma), plans to enrol 165 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#232of 1244 companies, score 22
- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +1
- registry trials +8
1 approved, 1 in phase 3, 0 earlier, 1 targets, 15 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
2014
Phase 3small molecule (structure undisclosed or not yet in PubChem)
KC1036 is an experimental small-molecule drug from Beijing Konruns Pharmaceutical in phase 3 trials for oesophageal cancer, ewing sarcoma and thymoma and thymic carcinoma, with its target not yet stated publicly.
ApprovedOral MEK1/2 inhibitor
Tunlametinib is a Chinese MEK inhibitor approved in 2024 for advanced melanoma with an NRAS mutation, a group with no targeted therapy elsewhere in the world, and in phase 3 trials with vemurafenib for BRAF-mutant disease and for colorectal cancer.
Similar pages
- TargetNRAS
Shares Tunlametinib, Melanoma, Colorectal cancer.
- CancerAcral melanoma
Shares Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma, Tunlametinib, Melanoma.
- CancerMucosal melanoma
Shares Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma, Tunlametinib, Melanoma.
- TargetMEK1/2
Shares Tunlametinib, Melanoma, Colorectal cancer.
cancers
drugs
Phase 3small molecule (structure undisclosed or not yet in PubChem)
ApprovedOral MEK1/2 inhibitor